ALKS Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

35.290

Open

34.120

VWAP

35.00

Vol

3.00M

Mkt Cap

6.00B

Low

34.000

Amount

98.00M

EV/EBITDA(TTM)

12.00

Total Shares

165.00M

EV

4.00B

EV/OCF(TTM)

8.00

P/S(TTM)

4.00

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Show More

Events Timeline

(ET)

2026-01-12

16:30:00

Avadel Pharmaceuticals Shareholders Approve Acquisition Scheme

2026-01-06 (ET)

2026-01-06

07:30:00

Alkermes Receives FDA Breakthrough Therapy Designation for Alixorexton

2026-01-06

07:30:00

Stock Up 77 Cents to $28.77 in Premarket Trading

2025-12-01 (ET)

2025-12-01

08:40:00

B. Riley Raises Centessa Price Target to $42, Maintains Buy Rating

2025-11-19 (ET)

2025-11-19

06:11:42

Alkermes Raises Acquisition Bid for Avadel Pharmaceuticals to $22.50 per Share

2025-11-17 (ET)

2025-11-17

06:11:58

Avadel board determines Lundbeck's proposal is better than Alkermes' offer

News

an image of Benzinga

Goldman Sachs Downgrades Super Micro Computer to Sell with $26 Price Target

an image of NASDAQ.COM

01-19NASDAQ.COM

ImmunityBio (IBRX) Shares Surge 39.8% on Positive QUILT-106 Study Data

an image of Yahoo Finance

01-19Yahoo Finance

Alkermes Receives FDA Breakthrough Therapy Designation for Alixorexton, Potentially Accelerating Development

an image of CNBC

Super Micro Computer Rated Sell, Medline Rated Buy by Analysts

an image of NASDAQ.COM

01-14NASDAQ.COM

Guess, NESR, and Alkermes Rated Buy with Strong Value Characteristics

an image of Yahoo Finance

01-12Yahoo Finance

Avadel Pharmaceuticals Shareholders Approve Alkermes Buyout

14 Analyst Rating

Wall Street analysts forecast ALKS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALKS is 46.17 USD with a low forecast of 37.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

3 Hold

0 Sell

Strong Buy

Current: 0.000

Low

37.00

Averages

46.17

High

58.00

Current: 0.000

Low

37.00

Averages

46.17

High

58.00

Jefferies

Hold

downgrade

$23

AI Analysis

2025-11-26

Reason

Jefferies

Price Target

$23

AI Analysis

2025-11-26

downgrade

Hold

Reason

Jefferies lowered the firm's price target on Avadel Pharmaceuticals (AVDL) to $22.50 from $23 and keeps a Hold rating on the shares as the firm expects the deal to be acquired by Alkermes (ALKS) to close in Q1 of 2026 after Lundbeck decided not to raise its November 14 offer. The firm now thinks the chances of a competing bid are unlikely and lowered its target to reflect Alkermes' November 18 offer to acquire Avadel for $22.50 per share, including $21 upfront and a $1.50 per share CVR.

Guggenheim

Buy

upgrade

$28 -> $43

2025-11-18

Reason

Guggenheim

Price Target

$28 -> $43

2025-11-18

upgrade

Buy

Reason

Guggenheim raised the firm's price target on Centessa (CNTA) to $43 from $28 and keeps a Buy rating on the shares following the "promising" preliminary readout from the ORX750 CRYSTAL-1 Ph2a study as well as the "relatively underwhelming" results from alixorexton in NT2 that were reported by Alkermes (ALKS).

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ALKS

Unlock Now

Valuation Metrics

The current forward P/E ratio for Alkermes Plc (ALKS.O) is 13.98, compared to its 5-year average forward P/E of 95.61. For a more detailed relative valuation and DCF analysis to assess Alkermes Plc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

95.61

Current PE

13.98

Overvalued PE

246.43

Undervalued PE

-55.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

6.17

Current EV/EBITDA

9.76

Overvalued EV/EBITDA

78.30

Undervalued EV/EBITDA

-65.96

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

5Y Average PS

3.60

Current PS

2.72

Overvalued PS

4.43

Undervalued PS

2.77

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

stocks with the most upside

Intellectia · 13 candidates

Market Cap: >= 5.00BAnalyst Consensus: Strong BuyEps Ttm: >= 0Target Price Upside Potential: MoreAbovePriceMonth Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

Uber Technologies Inc

175.00B

Axon Enterprise Inc

48.00B

Cheniere Energy Inc

45.00B

Nebius Group NV

25.00B

Futu Holdings Ltd

23.00B

Viper Energy Inc

14.00B

reduce to top 5

Intellectia · 35 candidates

Analyst Consensus: Strong BuyRelative Vol: >= 1.50Target Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA20Month Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

Viper Energy Inc

14.00B

Cipher Mining Inc

7.00B

Alkermes Plc

6.00B

CG Oncology Inc

5.00B

California Resources Corp

4.00B

Alliance Laundry Holdings Inc

4.00B

Best stocks with highest gains

Intellectia · 14 candidates

Market Cap Category: mid, largeRelative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20Month Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

Amgen Inc

185.00B

Vertex Pharmaceuticals Inc

117.00B

Takeda Pharmaceutical Co Ltd

51.00B

Biontech SE

30.00B

Royalty Pharma PLC

23.00B

Moderna Inc

19.00B

best Biotechnology/Health Tech gainers

Intellectia · 14 candidates

Market Cap Category: mid, largeRelative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20Month Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

Amgen Inc

185.00B

Vertex Pharmaceuticals Inc

117.00B

Takeda Pharmaceutical Co Ltd

51.00B

Biontech SE

30.00B

Royalty Pharma PLC

23.00B

Moderna Inc

19.00B

top Biotechnology/Health Tech For gainers

Intellectia · 14 candidates

Market Cap Category: mid, largeRelative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20Month Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

Amgen Inc

185.00B

Vertex Pharmaceuticals Inc

117.00B

Takeda Pharmaceutical Co Ltd

51.00B

Biontech SE

30.00B

Royalty Pharma PLC

23.00B

Moderna Inc

19.00B

market cap can be as low as possible

Intellectia · 26 candidates

Market Cap: >= 0Relative Vol: >= 1.50Beta: LowRisk, ModerateRiskWeekly Average Turnover: >= 1,000,000Pe Ttm: 5 - 25

Ticker

Name

Market Cap$

Abbott Laboratories

210.00B

NetEase Inc

83.00B

Garmin Ltd

39.00B

Telefonaktiebolaget LM Ericsson

32.00B

Royalty Pharma PLC

23.00B

Check Point Software Technologies Ltd

19.00B

which stocks show a great upside

Intellectia · 35 candidates

Analyst Consensus: Strong BuyBeta: LowRiskWeekly Average Turnover: >= 1,000,000Target Price Upside Potential: MoreAbovePriceMonth Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

Cheniere Energy Inc

45.00B

Viper Energy Inc

14.00B

Tetra Tech Inc

10.00B

Praxis Precision Medicines Inc

9.00B

Core Scientific Inc

6.00B

Alkermes Plc

6.00B

Whales Holding ALKS

Paradigm Biocapital Advisors LP

Commodore Capital LP

Frazier Life Sciences Management, LP

Avoro Capital Advisors LLC

Baker Bros. Advisors LP

EcoR1 Capital, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Alkermes Plc (ALKS) stock price today?

The current price of ALKS is 34.88 USD — it has increased 2.89 % in the last trading day.

What is Alkermes Plc (ALKS)'s business?

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

What is the price predicton of ALKS Stock?

Wall Street analysts forecast ALKS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALKS is46.17 USD with a low forecast of 37.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Alkermes Plc (ALKS)'s revenue for the last quarter?

Alkermes Plc revenue for the last quarter amounts to 394.00M USD, increased 4.24 % YoY.

What is Alkermes Plc (ALKS)'s earnings per share (EPS) for the last quarter?

Alkermes Plc. EPS for the last quarter amounts to 0.49 USD, decreased -10.91 % YoY.

How many employees does Alkermes Plc (ALKS). have?

Alkermes Plc (ALKS) has 1800 emplpoyees as of January 30 2026.

What is Alkermes Plc (ALKS) market cap?

Today ALKS has the market capitalization of 6.00B USD.